[Immune monitoring of the cancer patient: suppressor cells and NK cells].
Immune monitoring in cancer patients consists mainly in the analysis of the immune deficiency, the search for immune modulators and the examination of antitumor reactions. Suppressor cells have been demonstrated in Hodgkin's disease and lung carcinoma. Azimexon, a synthetic immune adjuvant has shown in anergic cancer patients powerfull restorative properties. Spontaneous cell mediated cytoxicity can been enhanced by interferon of lymphokines injections.
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D001388:Aziridines / Q000494:pharmacology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004342:Drug Hypersensitivity; D006689:Hodgkin Disease / Q000276:immunology*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced; D007372:Interferons / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000145:classification / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology*; D008222:Lymphokines / Q000494:pharmacology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D000276:Adjuvants, Immunologic; D001388:Aziridines; D008222:Lymphokines; C016866:azimexon; D007372:Interferons
L'exploration immunitaire du patient cancéreux: cellules suppressives et cellules NK.